Ferreras-Antolín L, Sharland M, Warris A. Management of invasive fungal disease in neonates and children. Pediatr Infect Dis J. 2019;38(6S Suppl. 1):S2–6.

Article  PubMed  PubMed Central  Google Scholar 

Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-60.

Article  PubMed  PubMed Central  Google Scholar 

Hu L, Dai TT, Zou L, Li TM, Ding XS, Yin T. Therapeutic drug monitoring of voriconazole in children from a tertiary care center in China. Antimicrob Agents Chemother. 2018;62(12):e00955-e1018.

Article  PubMed  PubMed Central  Google Scholar 

Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–71.

Article  CAS  PubMed  Google Scholar 

Singh G, Pitoyo CW, Aditianingsih D, Rumende CM. Risk factors for early invasive fungal disease in critically ill patients. Indian J Crit Care Med. 2016;20(11):633–9.

Article  PubMed  PubMed Central  Google Scholar 

Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases: estimate precision. J Fungi (Basel). 2017;3(4):57.

Article  PubMed  PubMed Central  Google Scholar 

Zhang MK, Rao ZG, Ma T, Tang M, Xu TQ, He XX, et al. Appropriate empirical antifungal therapy is associated with a reduced mortality rate in intensive care unit patients with invasive fungal infection: a real-world retrospective study based on the MIMIC-IV database. Front Med (Lausanne). 2022;9: 952611.

Article  PubMed  PubMed Central  Google Scholar 

Valle-T-Figueras JM, Renedo Miró B, Benítez Carabante MI, Díaz-de-Heredia C, Vima Bofarull J, Mendoza-Palomar N, et al. Voriconazole use in children: therapeutic drug monitoring and control of inflammation as key points for optimal treatment. J Fungi (Basel). 2021;7(6):456.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Owusu Obeng A, Egelund EF, Alsultan A, Peloquin CA, Johnson JA. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy. 2014;34(7):703–18.

Article  CAS  PubMed  Google Scholar 

John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 2019;15(11):881–95.

Article  CAS  PubMed  Google Scholar 

Duehlmeyer S, Klockau C, Yu D, Rouch J. Characterization of therapeutic drug monitoring practices of voriconazole and posaconazole at a pediatric hospital. J Pediatr Pharmacol Ther. 2021;26(1):26–32.

PubMed  PubMed Central  Google Scholar 

Jin H, Wang T, Falcione BA, Olsen KM, Chen K, Tang H, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tucker L, Higgins T, Egelund EF, Zou B, Vijayan V, Peloquin CA. Voriconazole monitoring in children with invasive fungal infections. J Pediatr Pharmacol Ther. 2015;20(1):17–23.

PubMed  PubMed Central  Google Scholar 

Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16(7):927–33.

Article  CAS  PubMed  Google Scholar 

Boast A, Curtis N, Cranswick N, Gwee A. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother. 2016;71(7):2031–6.

Article  CAS  PubMed  Google Scholar 

Chen J, Chan C, Colantonio D, Seto W. Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit. 2012;34(1):77–84.

Article  CAS  PubMed  Google Scholar 

Lin XB, Huang F, Tong L, Xia YZ, Wu JJ, Li J, et al. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: a prospective study in the intensive care unit. Int J Infect Dis. 2020;93:345–52.

Article  CAS  PubMed  Google Scholar 

Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother. 2012;67(11):2717–24.

Article  CAS  PubMed  Google Scholar 

Mori M, Fukushima K, Miharu M, Goto H, Yoshida M, Shoji S. A retrospective analysis of voriconazole pharmacokinetics in Japanese pediatric and adolescent patients. J Infect Chemother. 2013;19(1):174–9.

Article  CAS  PubMed  Google Scholar 

Gerin M, Mahlaoui N, Elie C, Lanternier F, Bougnoux ME, Blanche S, et al. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. Ther Drug Monit. 2011;33(4):464–6.

Article  CAS  PubMed  Google Scholar 

Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gijsen M, Vlasselaers D, Spriet I, Allegaert K. Pharmacokinetics of antibiotics in pediatric intensive care: fostering variability to attain precision medicine. Antibiotics (Basel). 2021;10(10):1182.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93.

Centers for Disease Control and Prevention. BMI Percentile Calculator for Child and Teen. Available online at: https://www.cdc.gov/healthyweight/bmi/calculator.html. Accessed 14 Jan 2022.

WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. Geneva:World Health Organization (2006). Available online at: https://www.who.int/childgrowth/standards/technical_report/en/. Accessed Sept 2023.

Bury D, Tissing WJE, Muilwijk EW, Wolfs TFW, Brüggemann RJ. Clinical pharmacokinetics of triazoles in pediatric patients. Clin Pharmacokinet. 2021;60(9):1103–47.

Article  PubMed  PubMed Central  Google Scholar 

Shi C, Xiao Y, Mao Y, Wu J, Lin N. Voriconazole: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2019;58(6):687–703.

Article  CAS  PubMed  Google Scholar 

van den Born DA, Märtson AG, Veringa A, Punt NC, van der Werf TS, Alffenaar JC, et al. Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model. Int J Antimicrob Agents. 2023;61(4): 106750.

Article  PubMed  Google Scholar 

Li X, Lai F, Jiang Z, Li M, Chen Z, Cheng J, et al. Effects of inflammation on voriconazole levels: a systematic review. Br J Clin Pharmacol. 2022;88(12):5166–82.

Article  PubMed  Google Scholar 

Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–76.

Article  PubMed  Google Scholar 

Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013;57(1):235–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang HM, Lee HJ, Cho EY, Yu KS, Lee H, Lee JW, et al. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. Pediatr Hematol Oncol. 2015;32(8):557–67.

Article  CAS  PubMed  Google Scholar 

Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, Henriet S, van der Sluis IM, Hanff LM, et al. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. Med Mycol. 2019;57(8):937–43.

Article  CAS  PubMed  Google Scholar 

Hanai Y, Hamada Y, Kimura T, Matsumoto K, Takahashi Y, Fujii S, et al. Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: a systematic review and meta-analysis. J Infect Chemother. 2021;27(2):151–60.

Article  CAS  PubMed  Google Scholar 

Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.

Article  CAS  PubMed  Google Scholar 

Choi SH, Lee SY, Hwang JY, Lee SH, Yoo KH, Sung KW, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer. 2013;60(1):82–7.

Article  CAS  PubMed  Google Scholar 

Shen K, Gu Y, Wang Y, Lu Y, Ni Y, Zhong H, et al. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases. Ther Adv Drug Saf. 2022;13:20420986221127504.

Article  CAS  PubMed  PubMed Central